<DOC>
	<DOCNO>NCT03099603</DOCNO>
	<brief_summary>This randomize , double blind , single center , ascend single dose study evaluate safety , tolerability , PK HTD1801 .</brief_summary>
	<brief_title>A Study HTD1801 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<criteria>1 . Age ≥18 ≤ 50 year 2 . Body mass index ( BMI ) ≥18.0 ≤ 30.0 kg/m2 3 . Current nonuser nicotine contain product ( &gt; 6 month ) 4 . Females must nonpregnant nonlactating , either surgically sterile ( e.g. , tubal occlusion , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) postmenopausal ≥12 month . The site try retrieve medical record document sterility , however , absence record exclude screen participant . If medical record obtain , serum urine pregnancy test conduct . Postmenopausal status confirm test FSH level ≥ 40 IU/mL screen amenorrheic female participant &lt; 50 year age . Males must surgically sterile ( &gt; 30 day since vasectomy viable sperm ) , abstinent engage sexual relation childbearing potential , participant partner must use acceptable , highly effective , contraceptive method Screening period 60 day last dose Study Drug . Acceptable method contraception use condom effective contraceptive female partner include : surgical sterilization ( e.g. , bilateral tubal ligation ) , hormonal contraception , intrauterine contraception/device ) . The Principal Investigator ass adequacy method contraception casebycase basis . 5 . Ability provide write informed consent . 1 . Participation investigational drug study within 30 day prior dose 5 halflives within last dose investigational product whichever longer . 2 . Current use prescription overthecounter ( OTC ) medication , include herbal product supplement , within 14 day prior Day 1 5 halflives , whichever longer . [ Use ≤2 g per day paracetamol ( acetaminophen ) allow prior study Investigator discretion . The reason use must list either subject 's baseline information adverse event . ] 3 . Any use nonsteroid antiinflammatory drug ( NSAIDs ) within 7 day prior dose . 4 . History serious adverse reaction hypersensitivity product component . 5 . Use parenterally administered protein antibody within 12 week screen . ( Note : Influenza vaccine allow ) 6 . Glucose6phosphate dehydrogenase ( G6PD ) deficiency . 7 . History weight loss &gt; 5 % 8 week prior screen . 8 . History active infection , mild viral illness , within 30 day prior dose . 9 . History alcohol illicit drug abuse judge Investigator within approximately 1 year 10 . Use nicotinecontaining product within 6 month prior Screening time study followup confirm urine cotinine screening . 11 . Presence clinically significant medical history , physical , laboratory , ECG finding , opinion Investigator , may potentially compromise safety subject , interfere aspect study conduct interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>